Peptide specificity of high-titer anti-glutamic acid decarboxylase (GAD)65 autoantibodies

被引:6
|
作者
Rharbaoui, F
Granier, C
Kellou, M
Mani, JC
van Endert, P
Madec, AM
Boitard, C
Pau, B
Bouanani, M
机构
[1] Fac Pharm Montpellier, CNRS, UMR9921, F-34060 Montpellier 2, France
[2] Hop Necker Enfants Malad, INSERM, U25, F-75743 Paris, France
[3] Fac Laennec, INSERM U449, F-69372 Lyon 8, France
[4] Hop St Vincent de Paul, INSERM U342, F-75014 Paris, France
关键词
insulin-dependent diabetes mellitus; glutamic acid decarboxylase; autoantibody epitope; synthetic peptide; spot synthesis;
D O I
10.1016/S0165-2478(98)00036-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To study systematically the linear epitope specificity of anti-glutamic acid decarboxylase (GAD) autoantibodies associated with insulin-dependent diabetes mellitus (IDDM), we produced 93 overlapping 12-residue synthetic peptides derived from the sequence of the human GAD65 protein and covering the entire length of the protein. These peptides were used as antigens in an enzyme immunoassay to screen the sera from 10 IDDM patients, all of which contained at high level autoantibodies directed against GAD65. Three out of ten (30%) IDDM patients had antibodies that reacted with one or more of the synthetic peptides, Two of the peptide-reactive IDDM sera, which also bound denatured recombinant GAD65 on western blots, had the highest titers of anti-CAD antibodies in ELISA assay. Moreover, the anti-CAD antibodies-CAD complexes formed with these sera were characterized by low dissociation rates, indicative of their good stability. A fine specificity analysis, using analogs of antigen peptide 1 (residues 1-12), allowed us to identify the residues at positions 5-9 (GSGFW) as critical for antibody recognition, (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:123 / 130
页数:8
相关论文
共 50 条
  • [1] Stiff Person Syndrome With Positive Anti-glutamic Acid Decarboxylase (GAD) Autoantibodies
    Maarad, Najoua
    Rahmani, Mounia
    Birouk, Nazha
    Taho, Adlaide
    Bnouhanna, Wadii
    Benabdeljlil, Maria
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [2] Rapid cognitive decline associated with anti-glutamic acid decarboxylase autoantibodies (GAD): a case report
    Martin Prieto, J.
    Rouco Axpe, I.
    Moreno Estebanez, A.
    Velasco Palacios, L.
    Boyero, S.
    Mendibe Bilbao, M.
    Agirre Beitia, G.
    Cabral Martinez, L.
    Sifontes Valladares, W.
    Rebollo Perez, A.
    Fernandez Rodriguez, V.
    Rodriguez-Antiguedad, A.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 562 - 562
  • [3] Cerebellar ataxia associated with anti-glutamic acid decarboxylase (anti-GAD) autoantibodies: a rare and puzzling disease
    Teive, Helio A. G.
    [J]. ARQUIVOS DE NEURO-PSIQUIATRIA, 2017, 75 (03) : 137 - 138
  • [4] Tremor of the mouth floor and anti-glutamic acid decarboxylase autoantibodies
    Vianello, M
    Morello, F
    Scaravilli, T
    Tavolato, B
    Giometto, B
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2003, 10 (05) : 513 - 514
  • [5] Cerebellar ataxia associated with anti-glutamic acid decarboxylase autoantibodies
    M. Vianello
    B. Tavolato
    M. Armani
    B. Giometto
    [J]. The Cerebellum, 2003, 2 : 77 - 79
  • [6] Cerebellar ataxia associated with anti-glutamic acid decarboxylase autoantibodies
    Vianello, M
    Tavolato, B
    Armani, M
    Giometto, B
    [J]. CEREBELLUM, 2003, 2 (01): : 77 - 79
  • [7] Hypersomnia in anti-glutamic acid decarboxylase 65 (GAD65) associated neurological syndromes: A pilot study
    Jeantin, Lina
    Gales, Ana
    Berzero, Giulia
    Leu, Smaranda
    Proust, Jeremy
    Giry, Marine
    Valyraki, Nefeli Eirini
    Birzu, Cristina
    Alentorn, Agusti
    Vidailhet, Marie
    Psimaras, Dimitri
    Arnulf, Isabelle
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023,
  • [8] DETECTION OF ANTI-GLUTAMIC ACID DECARBOXYLASE (GAD) ANTIBODIES IN IMMUNOGLOBULIN PRODUCTS
    Smith, Tukisa D.
    Cunningham-Rundles, Charlotte
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (03) : 261 - 261
  • [9] Successful immunotherapy for status epilepticus of a case with high titer of anti-glutamic acid decarboxylase antibodies
    Ohara, H.
    Kinoshita, M.
    Eura, N.
    Nishimori, Y.
    Yamanaka, M.
    Shimizu, H.
    Iguchi, N.
    Kiriyama, T.
    Tanaka, K.
    Sugie, K.
    [J]. EPILEPSIA, 2022, 63 : 268 - 269
  • [10] Prevalence of anti-glutamic acid decarboxylase (anti-GAD) antibodies in psychiatric patients
    Wojtanowska-Bogacka, M.
    Skibinska, M.
    Remlinger-Molenda, A.
    Wojciak, P.
    Kucharska, A.
    Abramowicz, M.
    Ferensztajn, E.
    Rybakowski, J. K.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S744 - S745